Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp director Ray Kurzweil reported the vesting and exercise of 650 restricted stock units into an equal number of shares of common stock on July 9, 2026. The RSUs converted on a one-for-one basis with no exercise price. Following the transaction, Kurzweil holds 13,320 shares of common stock directly.
UNITED THERAPEUTICS Corp director Nilda Mesa reported the vesting and conversion of equity awards. On July 9, 2026, 650 restricted stock units vested and were converted on a one-for-one basis into 650 shares of common stock. Following this compensation-related transaction, Mesa directly holds 5,678 shares of common stock.
UNITED THERAPEUTICS Corp director Judy D. Olian reported the vesting of equity awards. On July 9, 2026, 1,310 Restricted Stock Units vested and converted on a one-for-one basis into 1,310 shares of common stock at an exercise price of $0.00 per share. Following this conversion, Olian holds 5,555 shares of common stock directly, and the reported Restricted Stock Unit position is reduced to zero. The transactions reflect compensation-related vesting, not an open‑market purchase or sale.
UNITED THERAPEUTICS Corp director Christopher Patusky reported a compensation-related equity event. On July 9, 2026, 650 Restricted Stock Units vested and converted on a one-for-one basis into 650 shares of common stock at a stated price of $0.00 per share. Following this vesting, he held 2,140 shares of common stock directly, in addition to 1,100 shares held indirectly by trust. The RSU award involved in this transaction was fully converted, with no remaining units from that grant.
UNITED THERAPEUTICS Corp director Louis W. Sullivan reported the vesting of 650 restricted stock units on July 9, 2026, which converted on a one-for-one basis into 650 shares of common stock. Following the transaction, he holds 2,983 common shares directly and 867 common shares indirectly through a trust over which he has sole investment and voting power.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a series of transactions in Common Stock on July 10, 2026. She exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of Common Stock in multiple open-market trades at prices reported between $540.37 and $553.47 per share, all pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she holds 40,513 shares of Common Stock directly, plus additional indirect holdings in family trusts and stock options on 349,192 shares held indirectly through a family trust.
UNITED THERAPEUTICS Corp director Jan Malcolm received 650 shares of common stock on July 9, 2026 upon vesting of restricted stock units that converted one-for-one into common shares. On July 10, 2026, Malcolm executed an open-market sale of 325 common shares at $550.59 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Malcolm directly holds 450 common shares.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in common stock on July 9, 2026. She exercised 9,500 stock options at $135.42 per share and sold the resulting 9,500 shares in multiple open-market trades at weighted average prices around $548–$556, all pursuant to a pre-arranged Rule 10b5-1 trading plan. After these trades, she held 40,513 shares directly, along with additional indirect holdings through family trusts and stock options on 349,192 shares held in a family trust, as well as a plan that may cover the exercise of up to 1,734,410 stock options expiring on March 15, 2027.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares in a planned transaction. On 2026-07-08, she exercised options to acquire 9,500 shares of common stock at an exercise price of $135.42 per share and sold 9,500 shares in multiple open-market trades at weighted-average prices in the mid-$550 range. The filing states these option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares of common stock directly and continues to have additional indirect holdings through family trusts and her spouse, as well as stock options held indirectly on 349,192 underlying shares expiring on March 15, 2027.